Phoenix Business Journal – My View: How Policy Directives, Covid Drug Waiver Could Impact US health Care Investment
In this guest column, Arizona consultant Jim Rounds looks at the ramifications of a pair of policy directives being debated in Washington, including an intellectual property (IP) rights waiver that would remove patent protections for Covid vaccines, as well as a proposal by the Biden administration to invoke government price controls on medications, that could reduce industry R&D, potentially limiting new therapies and cures.
